SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is currently trending as its community eagerly anticipates the upcoming 4/20 cultural event, rallying around its mission to support global cannabis legalization and integrate real-world utility, often proclaiming itself 'like Bitcoin but way higher' with a 'Bongterm' outlook.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is experiencing heightened community discussion, driven by its innovative AI agent utility within the Base ecosystem and recent exchange listings, with many seeing it as undervalued and poised for significant growth despite some concerns regarding its volatility.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as soaring gold and silver prices fuel strong community discussion about its significant undervaluation and anticipated parabolic rally, even though some express frustration that the stock's performance has yet to fully reflect the metals' impressive ascent.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion after its compounded GLP-1 pill quickly prompted legal threats from Novo Nordisk and investigations from the FDA and DOJ, leading the company to halt the product's offering. Bears are calling the situation a major management misstep with severe financial consequences, while bulls argue it's a strategic de-risking move that generated extensive public attention for the brand.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending higher on strong earnings, an optimistic 2026 outlook driven by innovative medicine and medtech growth, and several recent regulatory approvals. Community discussion highlights its remarkable run to new highs, while also weighing significant ongoing talc litigation liabilities.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its community highlights the token's unique real-world asset (RWA) utility, with revenue from its 'Cocky Wings' food trailer business funding token buybacks and creating passive income opportunities in the 'COCK Arena' within the Cardano ecosystem.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics Inc. is experiencing significant investor interest following strong financial performance, a new multi-million-dollar battery order, and hitting fresh all-time highs. The community is actively discussing its potential as a long-term play in autonomous underwater technology and defense, further fueled by its key partnership with Anduril and prospects for a major exchange uplisting.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is drawing significant attention with community members fiercely debating its long-term potential, driven by expectations of smart contract integration and major exchange listings against a backdrop of vocal skepticism and claims of underperformance despite reported whale accumulation in its BlockDAG network.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE CRYPTO is experiencing heightened conversation, driven by its robust decentralized perpetual exchange's performance and aggressive token buybacks from fees, though ongoing debates center on its long-term stability versus concerns over token unlocks and "pump and dump" narratives.

Baker Hughes Co. is a holding company, which engages in the provision of oilfield products, services, and digital solutions. It operates through the Oilfield Services and Equipment (OFSE) and industrial and Energy Technology (IET) segments. The OFSE segment designs and manufactures products and provides services for onshore and offshore oilfield operations. The IET segment combines expertise, technologies, and services for industrial and energy customers including on and off-shore, LNG, pipeline and gas storage, refining, petrochemical, distributed gas, flow and process control, and industrial segments such as nuclear, aviation, automotive, marine, food and beverage, mining, cement and utilities. The company was founded in April 1987 and is headquartered in Houston, TX.

Baker Hughes Co - Ordinary Shares - Class A

Baker Hughes is trending on strong earnings results, fueled by record backlog and robust free cash flow, especially from its Industrial & Energy Technology segment. The community is actively discussing the company's strategic diversification into LNG, geothermal, and its crucial role as a "sleeper AI power play" providing energy infrastructure for data centers, leading to multiple analyst upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 68.0% during the third quarter, according to the company in its most recent 13F...

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5.26% and -0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6% - Time to Sell?

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.6% - Here's Why...

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold

Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>The trial is for the use of Nexiguran Ziclumeran (Nex-Z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.</li><li>The Phase 3 trial was suspended after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue.</li><li>The decision clears the way for Intellia to resume patient enrollment in the study.</li></ul>Shares of Intellia Therapeutics (NTLA) gained more than 13% on Tuesday morning as the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of Nexiguran Ziclumeran (Nex-Z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.A clinical hold is a delay or suspension of an ongoing clinical trial due to serious safety concerns.<h2 class="st-heading-2">Why Did FDA Suspend The Trial?</h2>The clinical hold was imposed in late October 2025 after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue that met the protocol-defined pausing criteria. Since then, Intellia has worked with the FDA to implement study modifications, including enhanced monitoring of liver-related lab tests.“With the clinical hold for MAGNITUDE-2 lifted, our team is focused on resuming patient enrollment as quickly as possible as we seek to advance this potential one-time treatment option for people living with ATTRv-PN,” said John Leonard, Intellia’s President and CEO.MAGNITUDE-2 is a randomized placebo-controlled study assessing the safety and effectiveness of Nex-Z in patients with ATTRv-PN. Following a protocol update, Intellia increased target enrollment to about 60 patients.<h2 class="st-heading-2">What’s Next?</h2>The decision clears the way for Intellia to resume patient enrollment in the study. Intellia said discussions with the FDA are ongoing regarding the separate MAGNITUDE Phase 3 trial of Nex-Z in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and the company will provide an update once a path forward is finalized.Nex-Z is a gene-editing therapy designed to permanently inactivate the TTR gene, which is key in producing a protein called transthyretin. The program has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, highlighting its potential to address serious unmet medical needs.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘high’ message volumes. <a href="https://stocktwits.com/symbol/NTLA">NTLA</a> was among the top trending tickers on the platform at the time of writing.One user believes the development should be good for the sector.<stembedurl>https://stocktwits.com/FredGS/message/642984565</stembedurl>Another user expects the stock to cross $20 by the end of the trading session. It is currently trading close to $15.<stembedurl>https://stocktwits.com/BrokersNY/message/642985076</stembedurl>The stock has gained nearly 50% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/what-triggered-qbts-stock-s-pre-market-rally-today/cmyaCXDR4LL">What Triggered QBTS Stock’s Pre-Market Rally Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About?

The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with Nex-Z 

Equity

AI Hits the Factory Floor, Defense Wins Get Bigger, and Gene Editing Regains Momentum

This morning’s news flow highlights how innovation is translating into execution across robotics, industrial automation, defense, and life sciences.

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.9% - Time to Buy?

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.9% - Still a Buy...

Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NTLA News

NTLAIntellia Therapeutics Inc